Clinical Trial: Study of IMC-P115C in Advanced PRAME-Positive Cancers

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07156136) titled 'Study of IMC-P115C in Advanced PRAME-Positive Cancers' on Aug. 26.

Brief Summary: Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.

Study Start Date: Nov. 07, 2024

Study Type: INTERVENTIONAL

Condition: PRAME Positive Cancer HLA-A*02:01-positive

Intervention: DRUG: IMC-P115C

IV infusion

Recruitment Status: RECRUITING

Sponsor: Immunocore Ltd

Published by HT Digital Content Services with permission from Health Daily Dige...